undamentalytics Newsletter
Sign in

Dianthus Therapeutics, Inc. income statement

In fiscal 2025, Dianthus Therapeutics, Inc. reported revenue of $2.0m, down 67.3% on the year before, operating income of −$178m (a -8739.3% margin) and net income of −$162m, or −$4.20 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192023Dec 20232024Dec 20242025Dec 2025
Revenue0000362
Research and development62841593383146
General and administrative381924182534
Operating income−9−36−60−83−48−102−178
Interest expense0——————
Income tax0000000
Net income−9−35−58−77−44−85−162
Diluted EPS−$3.26−$0.96−$1.56−$2.07−$8.45−$2.55−$4.20
Diluted shares (average)3m37m37m37m5m33m39m
EBITDA−9−35−59−81−48−102−178

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: DNTH vs KRSADNTH vs MCRBCLGN vs DNTH

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Dianthus Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Dianthus Therapeutics, Inc.